Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Antiglaucomatous Activity Of Betaxolol Chlorhydrate Sorbed Onto Different Isobutylcyanoacrylate Nanoparticle Preparations

L. Marchal-Heussler, P. Maincent, M. Hoffman, J. F. Spittler, P. Couvreur
Published 1990 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract The objectives of the present work were to evaluate the effects, on the reduction of the intra-ocular pressure (IOP) in glaucomatous rabbits, of different physico-chemical parameters such as: (1) the adsorption percentage of an antiglaucomatous drug (betaxolol chlorhydrate) onto isobutylcyanoacrylate nanoparticles; (2) the binding type of the drug onto the surface of the particles (hydrophobic or electrostatic). By modification of the surface charge, it was possible to adsorb either 25, 30 or 70% for the same drug concentration. When administered in glaucomatous rabbits, in comparison with commercial eye drops, the suspension with the highest adsorption level considerably lowered the overall therapeutic activity. The suspension with the lowest drug payload did not significantly increase the maximal intensity of the therapeutic response and tended to prolong the reduction of the IOP in time. It has been clearly shown that, regarding the ocular administration, the surface charge of the particles and the binding type of the drug onto the nanoparticles were much more important parameters than the drug adsorption percentage onto the nanoparticles.
This paper references
10.1016/0021-9797(85)90087-6
Particle size and size distribution of poly(butyl 2-cyanoacrylate) nanoparticles. II. Influence of stabilizers
S. J. Douglas (1985)
10.1002/JPS.2600751009
Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles.
P. Maincent (1986)
10.1016/0378-5173(83)90166-7
Pharmacokinetics and Distribution of a Biodegradable Drug-carrier
L. Grislain (1983)
10.1016/0378-5173(87)90050-0
A γ-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles
P. Fitzgerald (1987)
Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts.
L. Illum (1984)
10.1016/0378-5173(85)90007-9
Ocular disposition of poly-hexyl-2-cyano[3-14C]acrylate nanoparticles in the albino rabbit
R. Wood (1985)
10.1002/JPS.2600760211
Quantitation of the release of doxorubicin from colloidal dosage forms using dynamic dialysis.
P. Gupta (1987)
[Experimental alpha-chymotrypsin model of glaucoma in the rabbit: histopathological studies (author's transl)].
P. Vareilles (1979)
10.1159/000225763
Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice.
J. Kreuter (1983)
10.1016/0021-9797(84)90015-8
Particle size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles: I. Influence of physicochemical factors
S. J. Douglas (1984)
10.1016/0378-5173(86)90053-0
Enhancement of the myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles
T. Harmia (1986)



This paper is referenced by
10.5138/IJDD.2010.0975.0215.02007
Drug delivery to eye: Special reference to nanoparticles
Swarnali Das (2010)
10.1177/0885328209344003
Montmorillonite-Alginate Nanocomposites as a Drug Delivery System: Intercalation and In Vitro Release of Vitamin B1 and Vitamin B6
B. Kevadiya (2010)
10.1016/j.ijpharm.2009.03.004
Montmorillonite as a drug delivery system: intercalation and in vitro release of timolol maleate.
G. Joshi (2009)
10.1016/j.jneumeth.2008.10.036
Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease
B. Wilson (2009)
10.1081/DDC-52073
Oral Bioadhesive Drug Delivery Systems
M. Bruschi (2005)
Development and In-Vitro Evaluation of Nanosuspension Formulation Containing Acyclovir for the Treatment of Ocular Infections
R. Umamaheswari (2013)
10.1007/978-3-319-29346-2
Nano-Biomaterials For Ophthalmic Drug Delivery
Y. Pathak (2016)
10.1023/A:1011982428413
Cellular Uptake Study of Biodegradable Nanoparticles in Vascular Smooth Muscle Cells
Hearan Suh (2004)
10.20381/RUOR-4008
Guar Gum/Montmorillonite Nanocomposites and Their Potential Application in Drug Delivery
J. Dziadkowiec (2016)
10.30827/ARS.V45I3.5111
Estudio de la influencia de los factores de polimerización en la formación de nanopartículas de polibutil-cianoacrilato y la cinética de liberación de fármaco in vitro
L. Harivardhan-Reddy (2004)
10.1016/j.ijpharm.2020.119103
Development of an oral bentonite-based modified-release freeze-dried powder of vactosertib: Pharmacokinetics and anti-colitis activity in rodent models of ulcerative colitis.
Su Young Jung (2020)
10.3109/03639049509048095
New Ophthalmic Drug Delivery Systems
C. L. Bourlais (1995)
10.1002/APP.38635
Synthesis and in vitro release of guest drugs‐loaded copolymer nanospheres MMA/HEMA via differential microemulsion polymerization
A. B. Moustafa (2013)
10.1111/j.2042-7158.1996.tb03911.x
Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers
P. Calvo (1996)
10.1007/s12291-013-0364-6
Polybutylcyanoacrylate Nanoparticles and Drugs of the Platinum Family: Last Status
Dashti Rahmat Abadi Fatemeh (2013)
10.1023/A:1018936205485
Poly(ε-Caprolactone) Nanocapsules in Carteolol Ophthalmic Delivery
L. Marchal-Heussler (2004)
Estudo físico-químico comparativo de sistemas nanoestruturados contendo indometacina ou seu éster etílico e avaliação in vivo da atividade antiedematogênica
L. Cruz (2005)
10.1016/S1461-5347(98)00087-X
RECENT DEVELOPMENTS IN OPHTHALMIC DRUG DELIVERY
Shulin Ding (1998)
10.1016/0169-409X(95)00017-2
Microspheres and nanoparticles used in ocular delivery systems
A. Zimmer (1995)
10.1016/0021-9797(92)90079-2
Optimization of polyalkylcyanoacrylate nanoparticle preparation: Influence of sulfur dioxide and pH on nanoparticle characteristics
F. Lescure (1992)
10.1111/j.2042-7158.1991.tb03534.x
Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles
C. Losa (1991)
10.1016/S0065-3136(06)80004-X
2 Kinetic aspects in the design of prolonged action ocular drug delivery systems
A. Urtti (1995)
10.1016/S0142-9612(02)00080-7
Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.
R. Pignatello (2002)
10.1002/JPS.2600840721
Pefloxacine mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation.
M. Fresta (1995)
10.3109/03639049409050235
Association of netilmicin Sulphate to poly(Alkylcyanoacrylate) Nanoparticles: Factors Influencing particle delivery Behaviour
M. Fresta (1994)
10.4103/0250-474X.84582
Montmorillonite-Alginate Composites as a Drug delivery System: Intercalation and In vitro Release of Diclofenac sodium
B. Kevadiya (2010)
Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery.
B. Mandal (2010)
10.1016/S0079-6700(97)00048-8
Biodegradable polymers for the controlled release of ocular drugs
A. Merkli (1998)
10.1016/j.ejps.2009.03.009
Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study.
Rohit Mulik (2009)
10.1080/03639040701384942
Chitosan Nanoparticles for Prolonged Delivery of Timolol Maleate
S. Agnihotri (2007)
10.1007/978-3-642-29265-1_9
Nanotechnology in Ophthalmic Drug Delivery
Ali A Al-Kinani (2012)
10.1016/j.nano.2009.04.001
Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine.
B. Wilson (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar